Report from the First Clinical Trials on Alzheimer’s Disease (CTAD) Asia-China 2018 : Bringing together Global Leaders
Brief Reports
First Online:
- 6 Downloads
Abstract
Population of older adults in Asia, and particularly in China is increasing rapidly. Older population are at increased risk of Alzheimer’s disease (AD) and other dementias. Soon, the Chinese population with AD will represent almost half of the world’s AD population. There is a desperate need of disease modifying therapies to delay or slow the progression of AD, to tackle this emerging healthcare emergency. In this context, the first CTAD Asia-China conference was held in China to bring together Western and Asian leaders in AD. This meeting focused largely on how to develop successful trials in China, utilizing past experiences from the West.
Key words
Dementia Alzheimer’s disease China chinese clinical trials CTADReferences
- 1.Tanzi, R. E. The genetics of Alzheimer disease. Cold Spring Harb Perspect 1. Dementia statistics Alzheimer’s Disease International. https://doi.org/www.alz.co.uk/research/statistics. Accessed 1 Oct 2018Google Scholar
- 2.Cummings J, Fox N. Defining Disease Modifying Therapy for Alzheimer’s Disease. J Prev Alzheimers Dis 2017;4:109–115Google Scholar
- 3.Feng L, Li J, Yu J-T, et al. Editorial: Prevention of Alzheimer’s Disease in Chinese Populations: Status, Challenges and Directions. J Prev Alzheimers Dis 2018;5:90–94Google Scholar
- 4.Jia J, Wang F, Wei C, et al. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement 2014;10:1–9Google Scholar
- 5.Jia J, Wei C, Chen S, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement 2018;14:483–491Google Scholar
- 6.Jia J, Wei C, Chen S, et al. Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial. Alzheimers Dement (N Y) 2018;4:108–117Google Scholar
- 7.Cummings J, Fox N, Vellas B, Aisen P, Shan G. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force. J Prev Alzheimers Dis 2018;5:103–109Google Scholar
- 8.Vellas B, Aisen P, Weiner M, Touchon J. What We Learn from the CTAD (Clinical Trials Alzheimer’s Disease) 2018. J Prev Alzheimers Dis 2018;5:214–215Google Scholar
Copyright information
© Serdi Edition 2019